Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713986 | 0.92 | AKR1C3 (0.42) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL20032447 | 0.90 | AKR1C3 (0.39) | AKR1C3AKR1C2SCN9A | |
| SCHEMBL18713804 | 0.82 | AKR1C3 (0.42) | AKR1C3AKR1C2SCN9A | |
| SCHEMBL20032375 | 0.82 | TRPV1 (0.36) | CNR1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20032482 | 0.81 | TRPV1 (0.36) | CNR1 | |
| SCHEMBL20031922 | 0.80 | AKR1C3 (0.41) | AKR1C3AKR1C2TRPV3SCN9ACNR1 | |
| SCHEMBL21725513 | 0.80 | KCNH2 (0.35) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL18713979 | 0.80 | KCNH2 (0.38) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL20032350 | 0.80 | PTGS2 (0.34) | CNR1 | |
| SCHEMBL21366928 | 0.79 | KCNH2 (0.43) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | AKR1C3 157/4885AKR1C2 103/4885AKR1B10 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.